However, given the important role of the PI3K/AKT/mTOR pathway in normal cell metabolism, major on-target, off-tumor side effects, particularly hyperglycemia and hyperlipidemia, have impaired wide adaptation of these inhibitors in clinical practice [10]. Here, PIK3CA is linked to neoplasm.